| abstract |
MC-4 and / or MC-3 receptor ligands are described which have a structure in accordance with formula (1): (see formula) wherein B, X, Z, D, G, R, R1, R1 ' , R11, m, n, pyq are as described in the specification; the compounds are useful in the treatment of diseases that are mediated by the MC-4 receptor and / or the MC-3 receptor; as such, the invention is directed to methods for the treatment of body weight disorders, such as obesity, anorexia and cachexia; The invention also relates to the treatment of central nervous system depression, behavioral disorders, memory related disorders, cardiovascular function, inflammation, sepsis, septic shock, cardiogenic shock, hypovolemic shock, sexual dysfunction, erectile dysfunction, muscular atrophy, diseases associated with nerve repair and growth, and intrauterine fetal growth; Pharmaceutical compositions comprising the compounds of formula (1) are also described. |